Participants:
Present: Rajinder Suri (RS), Sonia Pagliusi (SP), Laura Viviani (LV), Benoit Hayman (BH), Prerna Kumar (PK), Tana McCauley (TM), Sivashen Cunden (SC), Sonia Villaseñor (SV).
Meeting started at 15h00 CET and finished at 16h00 CET.

1. The team welcomed Prerna.

2. Update on Webinars:
SC presented the results from the Webinars held during the first months of 2021. RS requested SC to report not only on the Webinars hosted by him but on all the webinars organized by DCVMN. RS suggested adding how many people attended by company and suggested to use a format keener to the eye. The one used for workshops is nice, but he invited SC not to stereotype and to create a different format for webinars. RS explained the difference between Webinars and workshops. A workshop is where people are involved in constructing and bring on the table to create an output. Webinar is a one-way traffic, one person is communicating to everybody. SC reports webinars. TM reports Workshops.

3. Contribution from sponsors:
SP said that we have 15 partners up to now. The contributions are set on a partnership proposal, they decide to which level to participate. There is a clear list of benefits that they can have depending on the level of sponsorship. It is geared to training, sharing scientific information. We try to avoid marketing exercise, without sharing scientific and technical information. We also try to avoid conflict of interest, and there is no negotiation.
This year we have already got 11 contributions. It is unrestricted educational grant; exclusively for educational activities, that includes webinars, workshops and AGM. The payments are used to keep the website, Webex, and logistics.
RS praised SP’s good job and expressed his full appreciation and compliments. RS asked how much money has come and how much yet to come; and which are the targets to increase the amounts substantially. RS also expressed a slight objection to the word Partner. A Partner is someone who shares profits and losses of an organization; which they are not. We should look at it differently and revise terminology for the coming AGM. BH and SV are supporting this initiative. It is a good idea to have everything captured on one platform so that everybody is aware and shall come into a system to be put in place. Any member of the team should approach new sponsors. RS requested to increase the vision of what could become a sponsorship this year.

4. New membership
Derived from the Africa Vaccine Summit, two potential members have been contacted. SP has sent an e-mail; RS said BH should now take initiatives to follow up with them. RS said we should look for more members. RS said we have two objectives: one is the membership fee, but also to increase the width of DCVMN in terms of total vaccine capacity. RS is approaching few other manufacturers, and anybody from the team is free to approach and get new members. COVID has taught us many things. The bigger the capacity, the more value you will have in the marketplace. We have the template of the email. The follow up process is that a process has to be created on how frequently we need to get in touch, so that by July everybody is on board. We should continue to focus on adding wherever we can to get results.

5. Progress on CHAI/CEPI/GAVI front
BH and SV are fully integrated into the commercial part. As far as CEPI and GAVI, BH is going to be the anchor; and as far as CHAI and PATH and CVIA is SV. At both fronts we have had a very good beginning. Yesterday we met with CHAI; they have deeper insights which can help our members to target the right kind of markets and products. They are very reliable team to work with and we should pay attention to what is agreed upon to get chased to get a win-win; SV to chase these ladies from CHAI to get the grid we talked about.
Regarding CEPI, BH will be hearing from them probably next week with a very crystal-clear targeted approach.

RS will lead until we have something settled on and then both BH and SV can take up on their own.

With GAVI, the MSS 5.0 whatever contributions we have provided are appreciated and we will continue to be in dialogue.
What to do and how to do is important to have clear goals.

BH asked if RS has interacted with UNICEF. RS told that we didn’t had a separate meeting with them, but all three of them are fully aligned. In case of a meeting, BH will also be there.

LV asked RS when you approach these organizations and try to set up common goals, is he also looking for opportunities for the technical work being done in the various Working Groups. Example, if PATH is interested in working on a new technology and it is something that could be interested in any of the established Working Groups, if these points are discuss at a certain point or is it coming later.
RS said there are so many opportunities coming soon with CEPI on Clinical and regulatory front, with PATH it is largely technical. BH and SV are the leads but not the technical experts. The technical part will be handled by LV, SC and TM as soon as we have something concrete with them. SV and BH will be leading the commercial part.

Regarding the regulatory part, LV, SC and TM should gear up themselves because Dr Nora Dellepiane has announced that she will leave DCVMN in July end. So don’t limit yourselves to webinars and workshops. The important thing is how to translate it into technology transfers, regulatory filing, handling of variant issues and become a leader.
There was a meeting on variants in which LV, SC and TM should have been invited, COVAX-CEPI workshop: Multivalent COVID-19 vaccines to help address emergence of variants: CMC and Clinical implications. They must be invited to all technical meetings.

6. AGM 2021: Progress report
SV said there have been several meetings with Biovac, the dates have been established for the 19th – 21st October. We are not certain yet if it will be hybrid or fully virtual. Biovac has found a couple of venues available for these dates (Hotel or convention center-Hotel. RS has requested Biovac to contact the Health minister to see if there is some hint. There are no objections so far to the dates. Simultaneously, we have to get prepared to be fully virtual. No objections to save the date. SV has evaluated 6 companies and she would only recommend 3.

7. AOB
Regarding platforms like Zoom, MS etc SC to clarify what we need and what is required to be done. SP has asked important questions to SC to clarify. Similarly share your thoughts and then review on total budget.

------------------
End of the document------------------

Rajinder Suri- CEO